Entresto Halves Renal Events in Preserved EF Heart Failure Patients Entresto Halves Renal Events in Preserved EF Heart Failure Patients

The PARAGON-HF trial of sacubitril/valsartan in patients with heart failure with preserved ejection fraction didn ' t meet its primary outcome but significantly improved a secondary renal endpoint.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news